Regorafenib Post-marketing Surveillance in Japan

• Status: Active, not recruiting
• Trial end date: 2022-01-31
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this study is to assess safety and effectiveness of Regorafenib using in real clinical practice

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer

Criteria

Inclusion Criteria:

• Patients who are treated with Regorafenib/ STIVARGA and meet the product label.

Exclusion Criteria:

• Patients who are treated with Regorafenib/ STIVARGA and don't meet the product label.